COMBINED THERAPY FOR HYPERTENSION AND CEREBRAL BLOOD FLOW INDICATORS
The impact of 6-month combined antihypertensive therapy with a calcium antagonist and an angiotensin-converting enzyme inhibitor (amlodipine with ramipril) on cerebral blood flow indicators in hypertensive patients working in the Far North has been evaluated.